26Jul 2021
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study

Oral semaglutide is the first oral glucagon‐like peptide‐1 receptor agonist for the treatment of type 2 diabetes, and showed significant benefits in glycaemic control and weight reduction versus active comparators in the PIONEER phase 3a randomized controlled trial programme. In this retrospective study, we present early data on the use of oral semaglutide in clinical practice, from the US IBM Explorys electronic health record database....

  • #endo-diabetology

Like

Save

Share